SCHEMBL4228934

SCHEMBL4228934

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC45CCCC(CC4)N5C)cc3)cc2)c(COC)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.38
MCHR1 Q99705 8/20 0.37
MCHR2 Q969V1 1/20 0.36
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
OPRM1 P35372 1/20 0.33
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742393 0.96 NPC1 (0.39) PKMMCHR1MCHR2KMT2AMAPT
SCHEMBL4238833 0.94 PKM (0.38) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4229247 0.91 MCHR1 (0.45) PKMMCHR1KDM4EALDH1A1KMT2A
SCHEMBL4236329 0.90 PKM (0.38) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4237744 0.90 PKM (0.38) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4237676 0.89 PNLIP (0.41) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4233302 0.89 PKM (0.38) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4239015 0.89 PKM (0.43) PKMMCHR1MCHR2KDM4EALDH1A1
SCHEMBL4237367 0.89 MCHR1 (0.39) PKMMCHR1ALDH1A1KMT2AMAPT
SCHEMBL4232012 0.87 EPHX2 (0.39) PKMMCHR1KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MCHR1 47/4885MCHR2 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.